All In Biotech

Drug Trial Radar · NCT04623541

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

194

Actual

Start

Nov 25, 2020

Primary completion

Dec 2027

Study completion Feb 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie; Eli Lilly and Company
First posted
Nov 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + pirtobrutinib In Non-United States (US) Participants Only: Treatment-naïve (TN) high risk (HR) (CLL): • epcoritamab + pirtobrutinib Combination therapy for Richter's Syndrome (RS): * epcoritamab + lenalidomide * epcoritamab + R-CHOP (i.e., rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine \[Oncovin®\] and prednisone). The study includes participants with R/R or TN HR CLL (non-US participants only)/small lymphocytic lymphoma (SLL) and participants with RS. The trial consists of two parts, a dose-escalation phase (phase Ib) and an expansion phase (phase II). Participants with RS are only included in the expansion phase. Epcoritamab will be injected subcutaneously (under the skin). Standard-of-care and combination treatments (venetoclax, pirtobrutinib, lenalidomide, and R-CHOP) will be given either orally (by mouth) or intravenously (in a vein). Study details include: * Study duration will be up to 5 years after the last participant's first treatment in the trial. * The treatment duration for each participant will be between 12 months (1 year) and 24 months (2 years), depending upon the treatment arm assigned. * The visit frequency will be either weekly, every other week, or monthly, depending upon the part of the study. All participants will receive active drug; no one will be given placebo.

Conditions

  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Richter's Syndrome
  • Treatment-naïve High Risk Chronic Lymphocytic Leukemia

Interventions

  • EpcoritamabBiological

    Epcoritamab will be administered subcutaneously in cycles of 28 days, (except Cycle 1 for high-dose cohorts = 35 days).

  • EpcoritamabBiological

    Epcoritamab will be administered subcutaneously in cycles of 21 days and 28 days.

  • rituximab, cyclophosphamide, doxorubicin, vincristine and prednisoneDrug

    R-CHOP will be administered intravenously (prednisone may be administered orally) in cycles of 21 days.

  • VenetoclaxDrug

    Venetoclax tablets will be administered orally once daily during the 5-week ramp up period in cycles of 28 or 35 days each.

  • EpcoritamabBiological

    Epcoritamab will be administered subcutaneously in cycles of 28 days.

  • LenalidomideDrug

    Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days.

  • EpcoritamabBiological

    Epcoritamab will be administered subcutaneously in cycles of 28 days.

  • PirtobrutinibDrug

    Pirtobrutinib tablets will be administered in cycles of 28 days.

  • EpcoritamabBiological

    Epcoritamab will be administered subcutaneously in cycles of 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Phase and Safety Run-in (R/R CLL arm): Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: During the first cycle for low dose cohorts (Cycle length = 28 days) and for high dose cohorts (Cycle length = 35 days)
  2. Dose Escalation Phase and Safety Run-in: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 5 years
  3. Dose Escalation Phase: Number of Participants with Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and Clinical Tumor Lysis Syndrome (CTLS)Time frame: Up to 5 years
  4. Expansion Phase: Overall Response Rate (ORR)Time frame: Up to 5 years

Locations

81 sites in 12 countries. Site status is shown where the registry gives one.

  • O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California Davis Medical Center Sacramento

    California City, California

  • City of Hope National Medical Center

    Duarte, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • David Geffen School of Medicine

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Memorial Healthcare System

    Pembroke Pines, Florida

  • National Institutes of Health

    Bethesda, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Henry Ford Medical Group

    Detroit, Michigan

  • Hackensack Meridian Hospital

    Hackensack, New Jersey

  • Northwell Health Cancer Institute

    Lake Success, New York

  • Columbia University Herbert Irving Comprehensive Cancer Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • University of Pennsylvania School of medicine

    Philadelphia, Pennsylvania

  • The University of Texas Southwestern Medical Centre

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • St. George Hospital

    Kogarah, New South Wales, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Barwon Health

    Geelong, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

  • AZ Sint-Jan

    Bruges, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Fakultni nemocnice Brno

    Brno, Czechia, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia, Czechia

  • Vseobecna Fakultni Nemocnice

    Prague, Nové Město, Czechia

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Nový Hradec Králové, Czechia

  • Fakultni Nemocnice Ostrava

    Ostrava, Poruba, Czechia

  • Aalborg University Hospital

    Aalborg, Denmark

  • Århus University Hospital

    Aarhus, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Roskilde Sygehus

    Roskilde, Denmark

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.